Barrett's esophagus : An update;Barrett-Ösophagus : Aktueller Stand

Pathologe

Volumn 33, Issue 1, 2012, Pages 5-16

  Baretton, G B ^a   Aust, D E ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Barrett's esophagus; Dysplasia; Esophageal adenocarcinoma; Gastroesophageal reflux disease; Intestinal metaplasia

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; CANCER STAGING; CELL TRANSFORMATION; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ESOPHAGOSCOPY; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; GOBLET CELL; HUMAN; LYMPH NODE METASTASIS; METAPLASIA; OBSERVER VARIATION; PATHOLOGY; PRECANCER; PROGNOSIS;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; ESOPHAGOSCOPY; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; GOBLET CELLS; HUMANS; LYMPHATIC METASTASIS; METAPLASIA; NEOPLASM STAGING; OBSERVER VARIATION; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857610687     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-011-1541-0     Document Type: Article

References (131)

1. Badreddine RJ, Prasad GA, Lewis JT et al (2010) Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol 8:248-253
2. Bani-Hani K, Martin IG, Hardie LJ et al (2000) Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 92:1316-1321 (Pubitemid 30660591)
3. Barrett MT, Sanchez CA, Prevo LJ et al (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22:106-109 (Pubitemid 29214816)
4. Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521-1530 (Pubitemid 37151509)
5. Behrens A, May A, Gossner L et al (2005) Curative treatment for high-grade intraepithelial neopla-sia in Barrett's esophagus. Endoscopy 37:999-1005 (Pubitemid 41489271)
6. Bosman FT, Carneiro F, Hruban RH et al (Hrsg) (2010) WHO classification of tumours of the digestive system. IARC, Lyon
7. Botterweck AA, Schouten LJ, Volovics A et al (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645-654 (Pubitemid 30612230)
8. Brown IS, Whiteman DC, Lauwers GY (2010) Fo-veolar type dysplasia in Barrett esophagus. Mod Pathol 23:834-843
9. Buttar NS, Wang KK, Sebo TJ et al (2001) Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastro-enterology 120:1630-1639 (Pubitemid 32523482)
10. Campomenosi P, Conio M, Bogliolo M et al (1996) p53 is frequently mutated in Barrett's metaplasia of the intestinal type. Cancer Epidemiol Biomarkers Prev 5:559-565 (Pubitemid 26235023)
11. Casson AG, Mukhopadhyay T, Cleary KR et al (1991) p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 51:4495-4499
12. Chandrasoma P, Makarewicz K, Wickramasing-he K et al (2006) A proposal for a new validated histological definition of the gastroesophageal junction. Hum Pathol 37:40-47 (Pubitemid 41790501)
13. Chandrasoma P, Wickramasinghe K, Ma Y et al (2007) Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly eso-phageal carcinomas. Am J Surg Pathol 31:569-575 (Pubitemid 46569041)
14. Chandrasoma P, Wijetunge S, Demeester SR et al (2010) The histologic squamo-oxyntic gap: an accurate and reproducible diagnostic marker of gastroesophageal reflux disease. Am J Surg Pathol 34:1574-1581
15. Chang Y, Liu B, Liu GS et al (2010) Short-segment Barrett's esophagus and cardia intestinal metaplasia: a comparative analysis. World J Gastro-enterol 16:6151-6154
16. Chao DL, Sanchez CA, Galipeau PC et al (2008) Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res 14:6988-6995
17. Chaves P, Crespo M, Ribeiro C et al (2007) Chromosomal analysis of Barrett's cells: demonstration of instability and detection of the metaplastic lineage involved. Mod Pathol 20:788-796 (Pubitemid 46933442)
18. Chennat J, Konda VJ, Ross AS et al (2009) Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcino-ma-an American single-center experience. Am J Gastroenterol 104:2684-2692
19. Coco D P, Goldblum JR, Hornick JL et al (2011) Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am J Surg Pathol 35:45-54
20. Cronin J, McAdam E, Danikas A et al (2011) Epidermal growth factor receptor (EGFR) is overex-pressed in high-grade dysplasia and adenocar-cinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am J Gastroenterol 106:46-56
21. Curvers WL, ten Kate FJ, Krishnadath KK et al (2010) Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 105:1523-1530
22. Jonge PJ de, Blankenstein M van, Looman CW et al (2010) Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 59:1030-1036
23. DeMeester SR, Wickramasinghe KS, Lord RV et al (2002) Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus. Am J Gastroenterol 97:2514-2523
24. Demicco EG, Farris AB III, Baba Y et al (2011) The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated ade-nocarcinoma. Mod Pathol 24:1177-1190
25. Dent J (2011) Barrett's esophagus: a historical perspective, an update on core practicalities and predictions on future evolutions of management. J Gastroenterol Hepatol 26 (Suppl 1) :11-30
26. Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049-2053 (Pubitemid 28525384)
27. Dorer R, Odze RD (2006) AMACR immunostai-ning is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol 30:871-877 (Pubitemid 44264978)
28. Downs-Kelly E, Mendelin JE, Bennett AE et al (2008) Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarci-noma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol 103:2333-2340
29. Ell C, May A, Pech O et al (2007) Curative endo-scopic resection of early esophageal adenocar-cinomas (Barrett's cancer). Gastrointest Endosc 65:3-10 (Pubitemid 44932158)
30. Feith M, Stein HJ, Mueller J et al (2004) Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis Esophagus 17:322-327 (Pubitemid 40123809)
31. Fleischer DE, Overholt BF, Sharma VK et al (2008) Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gas-trointest Endosc 68:867-876
32. Gatenby P, Ramus J, Caygill C et al (2009) Routinely diagnosed low-grade dysplasia in Barrett's oesophagus: a population-based study of natural history. Histopathology 54:814-819
33. Gatenby PA, Ramus JR, Caygill CP et al (2008) Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol 43:524-530 (Pubitemid 351536041)
34. Gerson LB, Shetler K, Triadafilopoulos G (2002) Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 123:461-467 (Pubitemid 34827190)
35. Glickman JN, Chen YY, Wang HH et al (2001) Phe-notypic characteristics of a distinctive multilaye-red epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am J Surg Pathol 25:569-578 (Pubitemid 32423353)
36. Glickman JN, Spechler SJ, Souza RF et al (2009) Multilayered epithelium in mucosal biopsy specimens from the gastroesophageal junction region is a histologic marker of gastroesophageal reflux disease. Am J Surg Pathol 33:818-825
37. Goldblum JR (2002) The significance and etiology of intestinal metaplasia of the esophagogast-ric junction. Ann Diagn Pathol 6:67-73 (Pubitemid 34157748)
38. Goldblum JR, Lauwers GY (2002) Dysplasia arising in barrett's esophagus: diagnostic pitfalls and natural history. Semin Diagn Pathol 19:12-19 (Pubitemid 34252298)
39. Goldblum JR, Richter JE, Vaezi M et al (2002) He-licobacter pylori infection, not gastroesophage-al reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am J Gastroenterol 97:302-311 (Pubitemid 34160754)
40. Goldblum JR (2010) Controversies in the diagnosis of Barrett esophagus and Barrett-related dy-splasia: one pathologist's perspective. Arch Pathol Lab Med 134:1479-1484
41. Gulizia JM, Wang H, Antonioli D et al (1999) Pro-liferative characteristics of intestinalized muco-sa in the distal esophagus and gastroesophageal junction (short-segment Barrett's esophagus) : a case control study. Hum Pathol 30:412-418 (Pubitemid 29177820)
42. Haggitt RC (1994) Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25:982-993 (Pubitemid 24313642)
43. Hahn H P, Blount PL, Ayub K et al (2009) Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am J Surg Pathol 33:1006-1015
44. Hamelin R, Flejou JF, Muzeau F et al (1994) TP53 gene mutations and p53 protein immunoreac-tivity in malignant and premalignant Barrett's esophagus. Gastroenterology 107:1012-1018 (Pubitemid 24294563)
45. Harrison R, Perry I, Haddadin W et al (2007) Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 102:1154-1161 (Pubitemid 46802035)
46. Hayes S, Ahmed S, Clark P (2011) Immunohisto-chemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence. J Clin Pathol 64:110-113
47. Hirota WK, Loughney TM, Lazas DJ et al (1999) Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastro-enterology 116:277-285 (Pubitemid 29055349)
48. Hong MK, Laskin WB, Herman BE et al (1995) Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 75:423-429
49. Hvid-Jensen F, Pedersen L, Drewes AM et al (2011) Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 365:1375-1383
50. Inadomi JM, Somsouk M, Madanick RD et al (2009) A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 136:2101-2114, e1-6
51. Ireland A P, Clark GW, DeMeester TR (1997) Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg 225:17-30 (Pubitemid 27026800)
52. Juhasz A, Mittal SK, Lee TH et al (2011) Prevalence of barrett esophagus in first-degree relatives of patients with esophageal adenocarcinoma. J Clin Gastroenterol 45:867-871
53. Kerkhof M, Dekken H van, Steyerberg EW et al (2007) Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histo-pathology 50:920-927 (Pubitemid 46850080)
54. Lambert R (2005) Update on the paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy 37:570-578 (Pubitemid 40775243)
55. Li H, Walsh TN, O'Dowd G et al (1994) Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 115:176-181 (Pubitemid 24057486)
56. Lisovsky M, Falkowski O, Bhuiya T (2006) Expression of alpha-methylacyl-coenzyme A racema-se in dysplastic Barrett's epithelium. Hum Pathol 37:1601-1606 (Pubitemid 44792228)
57. Liu W, Hahn H, Odze RD et al (2009) Metaplas-tic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol 104:816-824
58. Lomo LC, Blount PL, Sanchez CA et al (2006) Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort. Am J Surg Pathol 30:423-435 (Pubitemid 43740142)
59. Mahajan D, Bennett AE, Liu X et al (2010) Grading of gastric foveolar-type dysplasia in Barrett's esophagus. Mod Pathol 23:1-11
60. Maley CC, Galipeau PC, Li X et al (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 64:3414-3427 (Pubitemid 38657913)
61. Maley CC, Reid BJ (2005) Natural selection in neoplastic progression of Barrett's esophagus. Semin Cancer Biol 15:474-483 (Pubitemid 41318047)
62. McIntire MG, Soucy G, Vaughan TL et al (2011) MUC2 is a highly specific marker of goblet cell metaplasia in the distal esophagus and gastro-esophageal junction. Am J Surg Pathol 35:1007-1013
63. Mino-Kenudson M, Brugge WR, Puricelli WP et al (2005) Management of superficial Barrett's epithelium-related neoplasms by endoscopic muco-sal resection: clinicopathologic analysis of 27 cases. Am J Surg Pathol 29:680-686 (Pubitemid 40577880)
64. Mohammed IA, Streutker CJ, Riddell RH (2002) Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. Mod Pathol 15:611-616 (Pubitemid 34666464)
65. Montgomery E, Bronner MP, Goldblum JR et al (2001) Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 32:368-378 (Pubitemid 32378298)
66. Montgomery E, Bronner MP, Greenson JK et al (2002) Are ulcers a marker for invasive carcino ma in Barrett's esophagus? Data from a diagno stic variability study with clinical follow-up. Am J Gastroenterol 97:27-31 (Pubitemid 34059760)
67. Mosch C, Vieth M (2008) Does Barrett's without goblet cells exist?. Z Gastroenterol 46:1333-1334
68. Moss A, Bourke MJ, Hourigan LF et al (2010) En-doscopic resection for Barrett's high-grade dy-splasia and early esophageal adenocarcino-ma: an essential staging procedure with longterm therapeutic benefit. Am J Gastroenterol 105:1276-1283
69. Nicholson A, Jankowski J (2009) Editorial: One small step for metaplasia, but one giant leap for biomarkers is needed. Am J Gastroenterol 104:2681-2683
70. Oberg S, Johansson J, Wenner J et al (2001) En-doscopic surveillance of columnar-lined esophagus: frequency of intestinal metaplasia detection and impact of antireflux surgery. Ann Surg 234:619-626 (Pubitemid 33041764)
71. Odze R (2002) Cytokeratin 7/20 immunostai-ning: Barrett's oesophagus or gastric intestinal metaplasia? Lancet 359:1711-1713 (Pubitemid 34607080)
72. Odze RD, Glickman JN (2005) Significance of squamous metaplasia-like change in the esophagus. Am J Surg Pathol 29:1259-1261; author reply 1261-1253
73. Odze RD (2006) Diagnosis and grading of dy-splasia in Barrett's oesophagus. J Clin Pathol 59:1029-1038 (Pubitemid 44570324)
74. Odze RD (2008) Update on the diagnosis and treatment of Barrett esophagus and related neo-plastic precursor lesions. Arch Pathol Lab Med 132:1577-1585
75. Odze RD, Maley CC (2010) Neoplasia without dy-splasia: lessons from Barrett esophagus and other tubal gut neoplasms. Arch Pathol Lab Med 134:896-906
76. Ormsby AH, Goldblum JR, Rice TW et al (1999) Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 30:288-294 (Pubitemid 29125148)
77. Ormsby AH, Kilgore S P, Goldblum JR et al (2000) The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett's esophagus. Mod Pathol 13:614-620 (Pubitemid 30436796)
78. Ormsby AH, Petras RE, Henricks WH et al (2002) Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 51:671-676 (Pubitemid 35216854)
79. Paraf F, Flejou JF, Pignon JP et al (1995) Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases. Am J Surg Pathol 19:183-191
80. Paulson TG, Reid BJ (2004) Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell 6:11-16 (Pubitemid 38903158)
81. Pech O, Behrens A, May A et al (2008) Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 57:1200-1206
82. Peters F P, Brakenhoff K P, Curvers WL et al (2008) Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest Endosc 67:604-609
83. Playford RJ (2006) New British Society of Gas-troenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 55:442
84. Prasad GA, Wu TT, Wigle DA et al (2009) Endo-scopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 137:815-823
85. Ramel S, Reid BJ, Sanchez CA et al (1992) Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gas-troenterology 102:1220-1228
86. Reid BJ, Haggitt RC, Rubin CE et al (1988) Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19:166-178 (Pubitemid 18091022)
87. Reid BJ (1991) Barrett's esophagus and esopha-geal adenocarcinoma. Gastroenterol Clin North Am 20:817-834
88. Reid BJ, Sanchez CA, Blount PL et al (1993) Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gas-troenterology 105:119-129 (Pubitemid 23234027)
89. Reid BJ, Levine DS, Longton G et al (2000) Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95:1669-1676 (Pubitemid 30485000)
90. Reid BJ, Prevo LJ, Galipeau PC et al (2001) Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96:2839-2848 (Pubitemid 32959522)
91. Reid BJ, Blount PL, Rabinovitch PS (2003) Bio-markers in Barrett's esophagus. Gastrointest En-dosc Clin N Am 13:369-397
92. Rex DK, Cummings OW, Shaw M et al (2003) Screening for Barrett's esophagus in colonosco-py patients with and without heartburn. Gastro-enterology 125:1670-1677 (Pubitemid 37500431)
93. Rice TW, Zuccaro G Jr, Adelstein DJ et al (1998) Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 65:787-792 (Pubitemid 28162480)
94. Riddell RH, Odze RD (2009) Definition of Barrett's esophagus: time for a rethink-is intestinal metaplasia dead? Am J Gastroenterol 104:2588-2594
95. Ronkainen J, Aro P, Storskrubb T et al (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129:1825-1831 (Pubitemid 41772961)
96. Rossi E, Villanacci V, Bassotti G et al (2010) TO-POIIalpha and HER-2/neu overexpression/ampli-fication in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology 57:81-89
97. Rucker-Schmidt RL, Sanchez CA, Blount PL et al (2009) Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol 33:886-893
98. Schnell TG, Sontag SJ, Chejfec G et al (2001) Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastro-enterology 120:1607-1619 (Pubitemid 32523480)
99. Shaheen NJ, Sharma P, Overholt BF et al (2009) Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 360:2277-2288
100. Sharma P, McQuaid K, Dent J et al (2004) A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 127:310-330 (Pubitemid 38962298)
101. Sharma P, Dent J, Armstrong D et al (2006) The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 131:1392-1399 (Pubitemid 44708937)
102. Sharma P, Falk GW, Weston AP et al (2006) Dy-splasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastro-enterol Hepatol 4:566-572 (Pubitemid 44308164)
103. Sharma P, Falk GW, Sampliner R et al (2009) Management of nondysplastic Barrett's esophagus: where are we now? Am J Gastroenterol 104:805-808
104. Skacel M, Petras RE, Gramlich TL et al (2000) The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 95:3383-3387
105. Skinner DB, Walther BC, Riddell RH et al (1983) Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 198:554-565
106. Smith RR, Hamilton SR, Boitnott JK et al (1984) The spectrum of carcinoma arising in Barrett's esophagus. A clinicopathologic study of 26 patients. Am J Surg Pathol 8:563-573 (Pubitemid 14055016)
107. Souza R F, Spechler SJ (2005) Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 55:334-351 (Pubitemid 41677376)
108. Spechler SJ, Zeroogian JM, Antonioli DA et al (1994) Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 344:1533-1536 (Pubitemid 24357710)
109. Spechler SJ (1997) Short and ultrashort Barrett's esophagus-what does it mean? Semin Gastroin-test Dis 8:59-67 (Pubitemid 27196623)
110. Spechler SJ (2002) Columnar-lined esophagus. Definitions. Chest Surg Clin N Am 12:1-13
111. Spechler SJ (2002) Clinical practice. Barrett's Esophagus. N Engl J Med 346:836-842
112. Spechler SJ (2002) Screening for Barrett's esophagus. Rev Gastroenterol Disord 2 (Suppl 2) :S25-S29 (Pubitemid 35422995)
113. Spechler SJ (2002) Barrett's esophagus and esophageal adenocarcinoma: pathogene-sis, diagnosis, and therapy. Med Clin North Am 86:1423-1445 (Pubitemid 36008456)
114. Spechler SJ, Fitzgerald RC, Prasad GA et al (2010) History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenter-ology 138:854-869
115. Spechler SJ, Sharma P, Souza RF et al (2011) American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 140:e18-e52
116. Srivastava A, Odze RD, Lauwers GY et al (2007) Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia. Am J Surg Pathol 31:1733-1741 (Pubitemid 350287572)
117. Takubo K, Vieth M, Aida J et al (2009) Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. Digestion 80:248-257
118. Triadafilopoulos G (2010) Blitzkrieg for barrett's esophagus containing early neoplasia. Clin Gas-troenterol Hepatol 8:7-9
119. Sandick JW van, Lanschot JB van, Felius L van et al (2002) Intestinal metaplasia of the esophagus or esophagogastric junction: evidence of distinct clinical, pathologic, and histochemical staining features. Am J Clin Pathol 117:117-125
120. Vizcaino A P, Moreno V, Lambert R et al (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99:860-868 (Pubitemid 34575705)
121. Wang KK, Sampliner RE (2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 103:788-797 (Pubitemid 351406009)
122. Wani S, Mathur SC, Curvers WL et al (2010) Greater interobserver agreement by endoscopic mu-cosal resection than biopsy samples in Barrett's dysplasia. Clin Gastroenterol Hepatol 8:783-788
123. Wani S, Falk G, Hall M et al (2011) Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adeno-carcinoma. Clin Gastroenterol Hepatol 9:220-227
124. Weinstein WM, Ippoliti AF (1996) The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc 44:91-95 (Pubitemid 26268669)
125. Weston A P, Sharma P, Mathur S et al (2004) Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastro-enterol 99:1657-1666 (Pubitemid 39237488)
126. Wild C P, Hardie LJ (2003) Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 3:676-684 (Pubitemid 37328822)
127. Wittekind C, Meyer HJ (Hrsg) (2010) TNM Klassifikation maligner Tumoren. Wiley-VCH, Weinheim
128. Yantiss RK (2010) Diagnostic challenges in the pathologic evaluation of Barrett esophagus. Arch Pathol Lab Med 134:1589-1600
129. Younes M, Lauwers GY, Ertan A et al (2011) The significance of "indefinite for dysplasia" grading in Barrett metaplasia. Arch Pathol Lab Med 135:430-432
130. Yu C, Zhang X, Huang Q et al (2007) High-fidelity DNA histograms in neoplastic progression in Barrett's esophagus. Lab Invest 87:466-472 (Pubitemid 46633121)
131. Zhu W, Appelman HD, Greenson JK et al (2009) A histologically defined subset of high-grade dy-splasia in Barrett mucosa is predictive of associated carcinoma. Am J Clin Pathol 132:94-100